Laurus Labs is an Indian pharmaceutical and biotechnology company headquartered in Hyderabad, Telangana. The company is engaged in the development and manufacture of active pharmaceutical ingredients (APIs), generic finished dosage forms, and contract development and manufacturing services. It is recognised as a significant supplier of APIs in the antiretroviral (ARV) therapeutic segment, with additional presence in oncology, cardiovascular, anti-diabetic, anti-asthmatic, and gastroenterology categories.
| Laurus Labs | |
|---|---|
| Type | Public limited company |
| Industry | Pharmaceuticals, biotechnology |
| Headquarters | Hyderabad, Telangana, India |
| Founder | Satyanarayana Chava |
| Key business lines | Active pharmaceutical ingredients, generic formulations, contract research and manufacturing, biotechnology |
| Stock exchanges | BSE, NSE |
The company was founded by Satyanarayana Chava, a chemist who previously held senior research and development positions at other Indian pharmaceutical firms. Laurus Labs began with a focus on producing APIs for antiretroviral therapy, supplying global procurement programmes that distribute HIV/AIDS medication in low- and middle-income countries. Over time, it expanded into finished dosage formulations and broadened its therapeutic portfolio.
Laurus Labs operates multiple manufacturing and research facilities in Andhra Pradesh and Telangana, including units at Visakhapatnam. Its operations are organised across distinct business divisions:
Laurus Labs completed its initial public offering and listed on the Bombay Stock Exchange and National Stock Exchange of India in December 2016. Following the listing, the company progressively diversified beyond APIs into formulations and biotechnology. The acquisition of Richcore Lifesciences, a Bengaluru-based biotechnology firm, marked its entry into the recombinant products and fermentation-based manufacturing space.
Laurus Labs is considered one of the larger Indian suppliers of antiretroviral APIs used in HIV treatment regimens distributed through international public health programmes. Its role in the global generic ARV supply chain places it among the Indian pharmaceutical companies contributing to access to affordable HIV medication. The company is also part of India's broader generic and CDMO export ecosystem.